ATTR Cardiac Amyloidosis: 5 Vital Clinical Insights

Why ATTR Cardiac Amyloidosis Matters

For decades, ATTR cardiac amyloidosis was treated as a rare curiosity that required endomyocardial biopsy to confirm. That framing is now obsolete. The disease is common, findable without biopsy, and — for the first time — modifiable with therapy that improves survival.

Transthyretin (TTR) is a liver-derived transport protein. When it destabilises and misfolds, it deposits as amyloid fibrils in the myocardial extracellular space, producing a restrictive, progressively thickened heart. Two forms exist: wild-type (ATTRwt), typically in men over 70, and hereditary or variant (ATTRv), driven by TTR gene mutations.

The prevalence signal is consistent. A prospective study of 120 patients admitted with heart failure with preserved ejection fraction (HFpEF) found moderate-to-severe cardiac tracer uptake in 13.3% (95% CI 7.2–19.5). Broader prospective HFpEF and mildly-reduced-ejection-fraction cohorts have reported figures around 5–8%, so the true burden depends heavily on how patients are selected.

Why this matters clinically: ATTR cardiac amyloidosis is progressive and, untreated, carries a median survival historically reported at roughly two to six years from diagnosis. Because treatment benefit is greatest earlier in the disease, the cost of a missed or delayed diagnosis is measured in preventable decline.

Available Approaches

The approaches to this clinical problem fall into two linked stages: confirming the diagnosis without a biopsy, and then modifying the disease. The comparative evidence base for both stages is summarised below; every figure was checked against a retrieved primary source in preparing this review.

Non-biopsy diagnosis: the pathway that changed practice

The single most consequential advance in ATTR cardiac amyloidosis is that most cases can now be confirmed without histology. The pathway is short but unforgiving of shortcuts.

First comes suspicion from the red flags, supported by echocardiography or cardiac MRI showing increased wall thickness and infiltrative features. Then two tests run in parallel: a screen for a monoclonal protein and a bone scintigraphy scan.

The evidence for the pathway comes from a multicentre analysis of 1,217 patients with suspected cardiac amyloidosis. Grade 2 or 3 myocardial radiotracer uptake, graded against bone uptake, combined with the absence of a monoclonal protein in serum and urine, had a specificity and positive predictive value of 100% (95% CI 98.0–100) for ATTR. Grade 2–3 uptake considered alone was 91% sensitive and 87% specific, with false positives arising almost entirely from AL disease.

Once ATTR is confirmed, TTR gene sequencing separates wild-type from hereditary disease. This distinction is not academic: a pathogenic variant carries family-screening implications and can alter prognosis and monitoring.

Transthyretin stabilizers

Stabilizers bind the TTR tetramer and prevent it from dissociating into the misfolding-prone monomers that seed amyloid. They slow new fibril formation rather than clearing established deposits, which is why earlier treatment matters.

Tafamidis was the first agent to change outcomes. In the ATTR-ACT trial, 441 patients were randomised to tafamidis or placebo for 30 months. Tafamidis reduced all-cause mortality, with a hazard ratio of 0.70 (95% CI 0.51–0.96), and lowered cardiovascular-related hospitalisations, with a rate ratio of 0.68 (95% CI 0.56–0.81). It also slowed the decline in walk distance and quality of life. Strong evidence therefore supports tafamidis as disease-modifying therapy, and it carries a guideline-level recommendation.

Acoramidis is a next-generation stabilizer achieving near-complete (≥90%) TTR stabilisation. In ATTRibute-CM, 632 patients received acoramidis or placebo over 30 months. The trial met its primary hierarchical endpoint of mortality, cardiovascular hospitalisation, NT-proBNP and walk distance, with a win ratio of 1.8 (95% CI 1.4–2.2). The mortality signal was favourable but numerical, with a hazard ratio of 0.77 and a 6.4% absolute reduction. Acoramidis gained regulatory approval for the cardiomyopathy indication in late 2024.

Diflunisal, an older NSAID, also stabilises TTR and is sometimes used off-label. Its randomised evidence lies mainly in transthyretin polyneuropathy rather than cardiomyopathy, and its fluid-retention, renal and gastrointestinal risks make it problematic in heart failure. It is best regarded as a limited-evidence option requiring careful selection.

Transthyretin silencers

Silencers work upstream, reducing hepatic production of the amyloidogenic protein rather than stabilising it. Patisiran and vutrisiran are RNA-interference agents; the antisense oligonucleotides inotersen and eplontersen act by a related mechanism.

Patisiran was tested for cardiomyopathy in APOLLO-B, which randomised 360 patients to intravenous patisiran or placebo for 12 months. Patisiran preserved functional capacity: the median between-group difference in 6-minute walk distance was 14.69 m (95% CI 0.69–28.69) in favour of treatment, and quality of life improved. However, the secondary composite of mortality, cardiovascular events and walk distance was not statistically significant. On that basis, patisiran was not approved for the cardiomyopathy indication, though it remains approved for hereditary transthyretin polyneuropathy.

Vutrisiran produced the strongest silencer data in HELIOS-B, which randomised 655 patients to subcutaneous vutrisiran or placebo, some already receiving tafamidis. Vutrisiran reduced the primary composite of death and recurrent cardiovascular events, with a hazard ratio of 0.72 (95% CI 0.56–0.93). All-cause mortality, a secondary endpoint, was also reduced on longer follow-up (HR 0.64, 95% CI 0.46–0.88). The benefit held in patients already taking a stabilizer, and vutrisiran was approved for the cardiomyopathy indication in 2025.

Beyond these, gene-editing approaches that switch off hepatic TTR production are in early-phase clinical study. They are promising but investigational, and no outcome data support their routine use yet.

Quality and Consistency of the Evidence

The evidence base is unusually coherent for a rare disease, built on several adequately powered randomised trials and one large diagnostic-accuracy study. Strength varies by claim.

• Non-biopsy diagnosis (high). Grade 2–3 uptake with a negative monoclonal-protein screen carries a positive predictive value of 100% (95% CI 98.0–100) for ATTR in a multicentre cohort — provided AL is excluded.
• Tafamidis mortality benefit (high). A pre-specified primary analysis in a phase 3 RCT showed a significant reduction in all-cause mortality and hospitalisation.
• Vutrisiran composite benefit (high). A significant reduction in death plus cardiovascular events, consistent across subgroups and additive to background tafamidis.
• Acoramidis mortality effect (moderate). A convincing hierarchical composite, but the standalone mortality reduction was numerical rather than independently significant.
• Patisiran in cardiomyopathy (moderate). A genuine functional benefit that did not reach significance on the composite or on survival.
• Diflunisal and combination strategies (low). Off-label stabilizer use rests on polyneuropathy data, and combination-versus-monotherapy evidence is limited.

No signal here rests on a single small study, and effect directions are consistent across trials, which strengthens confidence in the central conclusions even where precise magnitudes differ.

Practical Implications

The evidence supports a small number of practical shifts, framed here as what the data justify rather than as directives.

Sustained suspicion is the first. In an older adult with HFpEF and increased wall thickness — particularly alongside bilateral carpal tunnel syndrome, spinal stenosis, biceps tendon rupture, or intolerance to standard heart-failure drugs — an amyloid work-up is reasonable, and a normal ECG voltage should not close the question.

Sequence matters in the work-up. Screening for a monoclonal protein with serum and urine immunofixation and free light chains belongs before a bone scan is trusted, because a positive scan with a monoclonal protein cannot confirm ATTR and instead points toward biopsy to exclude AL. Where the scan shows grade 2–3 uptake and the monoclonal screen is negative, a non-biopsy ATTR diagnosis is supported, and TTR sequencing then defines the subtype.

Because treatment benefit is greatest earlier, deferring the work-up carries a real cost. Disease-modifying therapy with a stabilizer or vutrisiran is now guideline-supported, with agent choice individualised to route, tolerability and access. Meanwhile, congestion is managed largely with diuretics, since neurohormonal drugs are often poorly tolerated in this population.